Trial | NCT00848562  Report issue

Title

Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients
Oral Nicorandil to Reduce Cardiac Death After Coronary Revascularization in Hemodialysis Patients: A Randomized Trial

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    nicorandil ...

  • Study Participants

    129
Survival after invasive coronary revascularization is worse in patients with chronic kidney disease than in those without it. The investigators aimed to examine whether oral administration of nicorandil, a hybrid of nitrate and adenosine triphosphate-sensitive potassium channel opener, could improve the survival of end-stage renal disease patients with coronary artery disease by inhibiting cardiac death after coronary revascularization.
Study Started
Jan 31
2002
Primary Completion
Dec 31
2006
Study Completion
Dec 31
2006
Last Update
Feb 20
2009
Estimate

Drug Nicorandil

Oral administration of nicorandil (15 mg/day)

Nicorandil Experimental

Criteria 

Inclusion Criteria:

Hemodialysis patients with coronary artery disease who had undergone a successful first PCI with bare-metal stents between July 1, 2001 and December 31, 2003.

Exclusion Criteria:

Subjects with moderate or worse cardiac valvular disease or old myocardial infarction at the point of first PCI.
No Results Posted